Inscription Capital’s Myriad Genetics MYGN Stock Holding History

Inscription Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,955	Closed	-$67.3K	–	839
2026 Q1	$67.3K	Sell	14,955 -8,417	-36%	-$43.9K	0.01%	701
2025 Q4	$144K	Buy	+23,372	New	+$169K	0.01%	629

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Inscription Capital's MYGN Position: Q2 2026 in Review

Inscription Capital sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 14,955 shares — an estimated $67.3K sold.

Inscription Capital first reported a position in MYGN in Q4 2025 and held it in 2 quarters. The position peaked at $144K in Q4 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Inscription Capital reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
Inscription Capital sold 14,955 Myriad Genetics shares in Q2 2026, an estimated $67.3K.
Inscription Capital first reported a position in Myriad Genetics in Q4 2025 and held it in 2 quarters.
Inscription Capital's Myriad Genetics position peaked at $144K in Q4 2025.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.